JP2022549510A5 - - Google Patents

Info

Publication number
JP2022549510A5
JP2022549510A5 JP2022519572A JP2022519572A JP2022549510A5 JP 2022549510 A5 JP2022549510 A5 JP 2022549510A5 JP 2022519572 A JP2022519572 A JP 2022519572A JP 2022519572 A JP2022519572 A JP 2022519572A JP 2022549510 A5 JP2022549510 A5 JP 2022549510A5
Authority
JP
Japan
Prior art keywords
alkyldiyl
peg
pep
aminobenzazepine
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022519572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549510A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/053224 external-priority patent/WO2021067242A1/en
Publication of JP2022549510A publication Critical patent/JP2022549510A/ja
Publication of JP2022549510A5 publication Critical patent/JP2022549510A5/ja
Ceased legal-status Critical Current

Links

JP2022519572A 2019-09-30 2020-09-29 アミド結合したアミノベンズアゼピン免疫複合体、及びその使用 Ceased JP2022549510A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908253P 2019-09-30 2019-09-30
US62/908,253 2019-09-30
PCT/US2020/053224 WO2021067242A1 (en) 2019-09-30 2020-09-29 Amide-linked, aminobenzazepine immunoconjugates, and uses thereof

Publications (2)

Publication Number Publication Date
JP2022549510A JP2022549510A (ja) 2022-11-25
JP2022549510A5 true JP2022549510A5 (cg-RX-API-DMAC7.html) 2023-09-29

Family

ID=72840675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519572A Ceased JP2022549510A (ja) 2019-09-30 2020-09-29 アミド結合したアミノベンズアゼピン免疫複合体、及びその使用

Country Status (11)

Country Link
US (1) US20220347310A1 (cg-RX-API-DMAC7.html)
EP (1) EP4038053A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022549510A (cg-RX-API-DMAC7.html)
KR (1) KR20220077131A (cg-RX-API-DMAC7.html)
CN (1) CN114746404A (cg-RX-API-DMAC7.html)
AU (1) AU2020359446A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006001A2 (cg-RX-API-DMAC7.html)
CA (1) CA3152601A1 (cg-RX-API-DMAC7.html)
IL (1) IL291760A (cg-RX-API-DMAC7.html)
MX (1) MX2022003740A (cg-RX-API-DMAC7.html)
WO (1) WO2021067242A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CA3176626A1 (en) * 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
CA3200056A1 (en) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-her2 immunoconjugates, and uses thereof
US20220195066A1 (en) * 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
CN117769439A (zh) * 2021-03-26 2024-03-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
CN117940168A (zh) * 2021-03-26 2024-04-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
EP4342884A4 (en) * 2021-05-19 2025-10-29 Shanghai De Novo Pharmatech Co Ltd Compound containing nitrogen, conjugate containing said compound, and associated use
US20250000995A1 (en) * 2021-10-29 2025-01-02 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
EP4450496A4 (en) * 2021-12-16 2025-12-24 Duality Biologics Suzhou Co Ltd TLR MODULATOR AND ITS USAGE
WO2023154302A1 (en) * 2022-02-09 2023-08-17 Bolt Biotherapeutics, Inc. Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses
TW202339806A (zh) * 2022-02-09 2023-10-16 美商博特生物治療公司 8—磺醯基—苯并氮呯免疫結合物及其用途
JP2025537044A (ja) * 2022-09-30 2025-11-13 シャンハイ ドーァ ノボ ファーマテック カンパニー,リミティド ベンザゼピン誘導体、それを含む複合体およびその応用
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US723288A (en) 1901-10-26 1903-03-24 Harry South Lewis Cipher-key for cryptographic codes.
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
WO2005086875A2 (en) 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20070014795A1 (en) 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
NZ569204A (en) 2005-12-21 2012-03-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び/又は予防用医薬組成物
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
MX348579B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
ES2672695T3 (es) 2011-08-04 2018-06-15 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
KR101968499B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
IN2014KN01714A (cg-RX-API-DMAC7.html) 2012-02-21 2015-10-23 Toray Industries
ES2739380T3 (es) 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
MX357505B (es) 2012-02-21 2018-07-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AU2013223143B2 (en) 2012-02-21 2017-12-21 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CA2879185C (en) 2012-07-19 2021-08-24 Toray Industries, Inc. Method for detecting cancer
WO2014014082A1 (ja) 2012-07-19 2014-01-23 東レ株式会社 癌の検出方法
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
EP3233835B1 (en) * 2014-12-18 2019-01-23 F.Hoffmann-La Roche Ag Benzazepine sulfonamide compounds
HUE042563T2 (hu) * 2015-03-06 2019-07-29 Hoffmann La Roche Benzazepin-dikarboxamid vegyületek
MX383893B (es) * 2015-11-02 2025-03-14 Ventirx Pharmaceuticals Inc Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar el cáncer.
EP3464274B1 (en) * 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Benzazepine dicarboxamide compounds with secondary amide function
WO2017202704A1 (en) * 2016-05-23 2017-11-30 F. Hoffmann-La Roche Ag Benzazepine dicarboxamide compounds with tertiary amide function
EP3468963B1 (en) * 2016-06-12 2021-10-27 F. Hoffmann-La Roche AG Dihydropyrimidinyl benzazepine carboxamide compounds
WO2018079740A1 (ja) 2016-10-28 2018-05-03 東レ株式会社 癌の治療及び/又は予防用医薬組成物
CA3049791A1 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
AU2018236272B2 (en) * 2017-03-15 2022-03-31 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
WO2019084060A1 (en) * 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
SG11202101980VA (en) * 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates
WO2020056194A1 (en) * 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
JP2022537158A (ja) * 2019-06-13 2022-08-24 ボルト バイオセラピューティクス、インコーポレーテッド アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用

Similar Documents

Publication Publication Date Title
JP2022553702A5 (cg-RX-API-DMAC7.html)
JP2022537158A5 (cg-RX-API-DMAC7.html)
JP2023524271A5 (cg-RX-API-DMAC7.html)
JP2022546110A5 (cg-RX-API-DMAC7.html)
JP2022554094A5 (cg-RX-API-DMAC7.html)
JP2024523453A5 (cg-RX-API-DMAC7.html)
JP2025160318A5 (cg-RX-API-DMAC7.html)
JP2022512900A5 (cg-RX-API-DMAC7.html)
JP2022527114A5 (cg-RX-API-DMAC7.html)
CN112752759A (zh) 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物及其方法与用途
IL312845B2 (en) Extacan derivatives, charge-linkers, and their conjugates
JP2023553421A5 (ja) 抗cea免疫複合体、及びその使用
JP2022512643A5 (cg-RX-API-DMAC7.html)
JP2021152063A5 (cg-RX-API-DMAC7.html)
JP2022533069A5 (cg-RX-API-DMAC7.html)
JP2023527962A5 (cg-RX-API-DMAC7.html)
JP2021525730A5 (cg-RX-API-DMAC7.html)
JP2020534300A5 (cg-RX-API-DMAC7.html)
JP2023552792A5 (cg-RX-API-DMAC7.html)
JP2024501453A5 (cg-RX-API-DMAC7.html)
JP2024511088A5 (cg-RX-API-DMAC7.html)
JP2023505509A (ja) ポリエチレングリコール複合薬、ならびにその調製方法およびその使用
JP2024545787A5 (cg-RX-API-DMAC7.html)
JP2023552790A5 (cg-RX-API-DMAC7.html)
CN120826405A (zh) 具有靶向作用的偶联物及其制备方法和用途